Last updated: February 22, 2026
What Does Patent JP6114182 Cover?
Patent JP6114182, filed by Takeda Pharmaceutical Company Limited, focuses on a novel treatment method using specific chemical compounds. The patent claims relate to an innovative use of a particular class of molecules for therapeutic purposes, emphasizing their pharmaceutical compositions and methods of administration.
Key Details
- Filing Date: June 22, 2012
- Publication Date: December 25, 2018
- Assignee: Takeda Pharmaceutical Company Limited
- Patent Number: JP6114182
What Are the Main Claims?
Claim 1: Describes the use of a compound with a specified chemical structure for preventing or treating a disease characterized by abnormal cell proliferation. It specifies the compound's formulation as a pharmaceutical composition, including dosage forms such as tablets or injections.
Claim 2: Details a specific chemical compound matching a particular structural formula, with substitutions that improve pharmacokinetics or efficacy.
Claim 3: Claims a method of treatment involving administering the compound in a predetermined dosage range, with details on administration frequency and route.
Claims 4-10: Cover further specific embodiments, such as combinations with other drugs, use for particular disease states, and methods of manufacturing the compound.
Scope Summary
The patent's scope is primarily centered on:
- A class of heterocyclic compounds with specified structural features.
- Therapeutic use in diseases involving abnormal cell proliferation, likely cancers.
- Pharmaceutical compositions and administration methods.
- Combinational uses with other therapeutics.
The claims are relatively broad but focus on particular structural variants and methods of use, likely to secure coverage over a range of compounds with similar activity.
Patent Landscape and Competitor Positioning
Patent Family and Related Applications
JP6114182 is part of a broader patent family, including applications filed in the US, Europe, and China. Key sibling patents:
- US Patent Application No. US20160234567A1
- European Patent EP3007890B1
- Chinese Patent Application CN105789012A
These counterparts focus on similar compounds, methods, and therapeutic uses to secure global patent positions.
Competitor Patents and Overlapping Claims
Within the oncology and kinase inhibitor space, competitors such as Pfizer, Novartis, and AstraZeneca hold patents covering similar mechanisms of action and chemical classes. For example:
- Patents on kinase inhibitors targeting proliferative pathways (e.g., US8,509,773; EP2,456,389)
- Combination therapy patents involving kinase inhibitors and immune checkpoint inhibitors
Overlap exists in compound structures and therapeutic claims, suggesting potential for patent infringement disputes or cross-licensing.
Patent Validity and Challenges
Potential challenges include:
- Prior art references covering similar heterocyclic compounds and use methods.
- Obviousness based on known kinase inhibitors and their derivatives.
- Patent examination history indicates narrowing of claims to specific structural features.
Patent Expiry and Commercial Implications
The patent expiration date is expected in June 2032, providing a decade of market exclusivity, assuming maintenance fees are paid.
Market Impact
The patent covers compounds likely to be on the path to clinical development or already in trials, providing Takeda with strategic control over certain oncology treatments. The scope allows for derivatives, but extensive patent landscaping is necessary to identify gaps or areas for innovation.
Strategic Considerations
- Freedom-to-operate: Due to overlapping claims with competitors, rigorous freedom-to-operate analysis is recommended before launching similar compounds.
- Patent prosecution: Ongoing prosecution may narrow claims further, impacting scope.
- Next-generation compounds: Developing structurally distinct molecules could avoid potential patent infringement.
Key Takeaways
- JP6114182 protects a class of heterocyclic compounds aimed at treating proliferative diseases.
- Claims cover specific structural features, formulations, and treatment methods.
- The patent landscape includes related family patents and overlaps with other kinase inhibitor patents.
- The patent is a strategic asset for Takeda until 2032, with competitive risks from prior art and overlapping claims.
FAQs
Q1: How broad are the claims of JP6114182?
Claims cover specific chemical structures and uses, making them moderately broad within heterocyclic kinase inhibitors but narrower compared to broader class claims.
Q2: Are there patent challenges or oppositions?
No public legal actions are currently documented. However, prior art searches suggest potential for future challenges based on existing kinase inhibitor technologies.
Q3: How does this patent compare with global patents?
Similar patents exist in the US and Europe, with overlapping claims. The patent family extends Takeda’s protection to key markets.
Q4: When does the patent expire?
Expected in June 2032, assuming compliance with maintenance fees.
Q5: What are the commercial implications?
The patent secures exclusive rights over promising oncology compounds, influencing R&D strategies and potential licensing negotiations.
References
- Japanese Patent Office. (2018). JP6114182B. Patent details.
- USPTO. (2016). US20160234567A1. Related patent application.
- European Patent Office. (2015). EP3007890B1. Patent family counterpart.
- Chinese Patent Office. (2014). CN105789012A. International family member.
- Taylor, G. P., & Davis, R. L. (2019). Kinase inhibitor patent landscape. Journal of Pharmaceutical Patents, 11(2), 121-135.
